09 September 2013 : Original article
Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: A pilot studyQing-Wei DuABCD, Ji-Guang DingABCDEF, Qing-Feng SunABCDEFG, Liang HongACD, Fu-Jing CaiBC, Qing-Qing ZhouABDE, Yang-He WuBCD, Rong-Quan FuBC
Med Sci Monit 2013; 19:751-756
BACKGROUND: The aim of this study was to compare the effect of combination lamivudine (LAM) and adefovir dipivoxil (ADV) versus entecavir (ETV) monotherapy for naïve HBeAg-positive chronic hepatitis B (CHB) patients.
MATERIAL AND METHODS: Fifty enrolled patients with CHB were evenly divided into 2 groups: a group treated with of lamivudine (LAM) (100 mg/day) plus adefovir (ADV) (10 mg/day) combination, and a group treated with entecavir (ETV) (0.5 mg/day). Serum levels of ALT, AST, creatinine, bilirubin, HBsAg, HBeAg and HBV viral load, and genotypic resistance were analyzed at 0, 12, 24, 52, and 104 weeks. HBV DNA levels were determined by real-time PCR and HBsAg and HBeAg by chemiluminescence. Serum levels of ALT, AST, creatinine, and bilirubin were measured by an automatic biochemical analyzer. Data analysis was performed with SPSS 12.0 software.
RESULTS: There were no significant differences in the virological response (VR) rates between LAM+ADV and ETV cohorts at 24, 52, and 104 weeks (P>0.05). The HBeAg seroconversion rates were 28% and 20%, and the biochemical response (BR) rates were 88% and 84% at week 104 in the LAM+ADV and ETV groups, respectively. The rates of undetectable HBV DNA, HBeAg seroconversion, and ALT normalization rates were similar in both cohorts. No virological breakthrough or serious adverse effects were noted for any patient during the study period.
CONCLUSIONS: Both LAM + ADV combination therapy and ETV monotherapy were effective and safe in the treatment of naïve HBeAg-positive CHB patients. However, further studies are needed to obtain long-term results.
Keywords: Adenine - therapeutic use, Alanine Transaminase - blood, Analysis of Variance, Aspartate Aminotransferases - blood, Bilirubin - metabolism, Drug Combinations, Enzyme-Linked Immunosorbent Assay, Guanine - therapeutic use, Hepatitis B Surface Antigens - blood, Hepatitis B e Antigens - blood, Hepatitis B virus - drug effects, Hepatitis B, Chronic - drug therapy, Lamivudine - therapeutic use, Organophosphonates - therapeutic use, Pilot Projects
01 November 2023 : EditorialEditorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared
Med Sci Monit 2023; 29:e942960
30 Nov 2023 : Review articleDecoding the Neurological Sequelae of General Anesthesia: A Review
Med Sci Monit In Press; DOI: 10.12659/MSM.942740
30 Nov 2023 : Clinical ResearchEnhanced Pain Relief and Muscle Growth in Individuals with Low Back Instability: The Impact of Blood Flow R...
Med Sci Monit In Press; DOI: 10.12659/MSM.942508
29 Nov 2023 : Clinical ResearchComparative Analysis of Intramedullary Nail versus Plate Fixation for Fibula Fracture in Supination Externa...
Med Sci Monit In Press; DOI: 10.12659/MSM.941909
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical ResearchPrevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292